What You Should Know:
Pepper Bio, the “Google Maps for drug discovery,” today announced an oversubscribed $6.5 million seed round led by NFX with participation from Silverton Partners, Merck Digital Sciences Studio, Mana Ventures, Tensility Ventures, VSC Ventures, and more. Pepper Bio is the world’s first transomics company, which maps data across all the -omics layers and translates it into the fastest route for discovering new drugs, finding new uses for existing
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Vivodyne Secures $38M for AI-Powered Drug Discovery Platform
What You Should Know:
- Vivodyne, a biotech company that accelerates drug discovery by testing therapies on lab-grown human organs raises $38M in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures.
- The funding will support Vivodyne's development of a clinically predictive AI stack and discovery pipeline, which utilizes lab-grown human organ tissues to identify novel therapeutic targets and predict patient
Read More
Genentech, NVIDIA Partner to Revolutionize Drug Discovery with AI
What You Should Know:
- Genentech and NVIDIA today announced a multi-year strategic research collaboration that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development.
- The collaboration is designed to significantly enhance Genentech’s advanced AI research programs by transforming its generative AI
Read More
Clinical Trial Data Strategy: Shifting to Innovative Data Collection and Flow While Reducing Burden On Your Sites
In drug development, there is a critical focus on protocol design, because it is a key component to running a successful clinical trial. And, in traditional trial design, developing a data management strategy often comes after the protocol is finalized. This can leave study teams juggling between operationalizing the protocol and mapping out optimal data collection and flow in parallel. In today’s complex trial landscape, streamlining planning and processes is top of mind for all stakeholders,
Read More
Safety Intelligence is Redefining How Pharmacovigilance Teams Operate
The future of safety intelligence is now. New safety reporting and analytics advancements have redefined how pharmacovigilance (PV) teams operate by putting next-generation safety intelligence at the fingertips of those needing it most.
Teams that can streamline data flow and enable stakeholders to self-service real-time insights are delivering unprecedented value by enabling greater case management visibility and more informed, proactive decision-making.
Despite this, many PV
Read More
AI in Drug Discovery Market to Reach $4B by 2027
What You Should Know:
The AI in Drug Discovery market in terms of revenue was estimated to be worth $600M in 2022 and is poised to reach $4B by 2027, growing at a CAGR of 45.7% from 2022 to 2027 according to a new report published by MarketsandMarkets™. The report cites the growing need to curb the drug discovery cost & reduce the overall time taken in this process, the rising adoption of cloud-based applications and services, and the impending patent expiry of blockbuster
Read More
Q/A: IQVIA’s Global Lead Talks Unlocking AI for Drug Repurposing
In an interview with HIT Consultant, Nathan Sommerford, Global Lead for Drug Discovery and Development, IQVIA talks how unlocking artificial intelligence (AI) in drug repurposing is transforming pharma and biotech companies.
What are some of the challenges and problems associated with drug discovery “from scratch”?
Nathan Sommerford, Global Lead for Drug Discovery and Development, IQVIA: In the traditional drug discovery and development paradigm, it can cost up to $1.8 billion and
Read More
Drug Discovery Outsourcing Market Expected to Reach $7.5B by 2033
What You Should Know:
The drug discovery outsourcing market is expected to reach $3.75B in 2023 and is expected to grow at a steady CAGR of 7.2% and is expected to reach $7.52B by 2033, according to a new report by Future Market Insights.The research report on the drug discovery outsourcing market states that the pharmaceutical industry is expanding thoroughly with new extensions and high-end research programs.
AI Drug Discovery Outsourcing for Cost-Savings
The
Read More
PsychoGenics Launches AI Platform to Revolutionize Drug Discovery
What You Should Know:
- PsychoGenics Inc., a provider of AI-enabled phenotypic drug discovery and preclinical CRO services launches eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform.
The platform supports phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.
How eCube Works
eCube measures drug-induced changes to EEG spectra data and utilizes machine learning classifiers trained
Read More
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
What You Should Know:
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health
Read More
